MicuRx Pharmaceuticals

About:

MicuRx discovers and develops novel antimicrobials to treat drug-resistant infections and other diseases of significant unmet medical need

Website: http://micurx.com

Top Investors: Legend Capital, Delian Capital, 3E Bioventures, Morningside Group, Huagai Capital

Description:

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.